NCT00756691 is a clinical trial of 18F-FAZA in Hypoxic Tumours, sponsored by AHS Cancer Control Alberta.

Who is sponsoring NCT00756691?

NCT00756691 is sponsored by AHS Cancer Control Alberta.

What drugs are being tested in NCT00756691?

Interventions in NCT00756691: 18F-FAZA.

What condition does NCT00756691 study?

NCT00756691 studies Hypoxic Tumours.

Is NCT00756691 still recruiting?

NCT00756691 is currently withdrawn. Last updated 14 November 2017.

Last reviewed 2017-11-14 · How we verify

NCT00756691

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Radiopharmacokinetic and Radiodosimetric Phase I Imaging Study of 18F-FAZA

Withdrawn Last updated 14 November 2017

What this trial tests

trial testing 18F-FAZA in Hypoxic Tumours. Withdrawn.

Quick facts

Lead sponsor	AHS Cancer Control Alberta
Status	Withdrawn
Study type	OBSERVATIONAL

Drugs / interventions tested

18F-FAZA

Conditions studied

Hypoxic Tumours — all drugs for Hypoxic Tumours →

Sponsor

AHS Cancer Control Alberta — full company profile →

Who can join

18 and older, any sex, with Hypoxic Tumours. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hypoxia (little of no oxygen) is considered to be an important characteristic of a patient's tumour that may help predict patient outcomes and/or help inform patient management decisions. 18F-FAZA Positron Emission Tomography (PET) can detect hypoxic tumours because 18F-FAZA accumulates in hypoxic tissues. This study is being done to learn more about the processes by which 18F-FAZA is absorbed, distributed, metabolized (built-up and broken down) and eliminated by the body.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other AHS Cancer Control Alberta trials

Trials by the same sponsor.

NCT05128734 — Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) · Phase 2 · not yet recruiting
NCT06860542 — Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis · Phase 2 · recruiting
NCT05345847 — Steroid Sparing in Immune Related Hepatitis (irH) · NA · recruiting
NCT05407987 — Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery) · Phase 3 · recruiting
NCT05421416 — Loratadine for the Prevention of G-CSF-related Bone Pain · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00756691 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AHS Cancer Control Alberta
Last refreshed: 14 November 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00756691.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing